Filing Details

Accession Number:
0001209191-21-063273
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-05 19:47:31
Reporting Period:
2021-11-03
Accepted Time:
2021-11-05 19:47:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1020214 Cerus Corp CERS Surgical & Medical Instruments & Apparatus (3841) 680262011
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1459351 Dennis Kevin Green C/O Cerus Corporation
1220 Concord Ave Suite 600
Concord CA 94520
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-03 95,000 $3.75 248,740 No 4 M Direct
Common Stock Disposition 2021-11-03 81,615 $7.00 167,125 No 4 S Direct
Common Stock Disposition 2021-11-03 14,126 $7.00 152,999 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (Right to Buy) Disposition 2021-11-03 95,000 $0.00 95,000 $3.75
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2022-02-28 No 4 M Direct
Footnotes
  1. This transaction was executed pursuant to a 10b5-1 plan.
  2. This transaction was executed pursuant to a 10b5-1 plan. Includes shares required to be sold to cover commission and mandatory tax withholdings on the "sell to cover" transaction described above and does not represent a discretionary sale by the reporting person.
  3. The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.01 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
  4. One eighth (1/8th) of the shares subject to the Option vested six (6) months after the grant date, and one forty-eighth (1/48th) of the shares subject to the Option vested each month thereafter.
  5. Not applicable.